Multi-gene test - early BC patients - spared chemo

Options
cp418
cp418 Member Posts: 7,079
edited March 2016 in Clinical Trials, Research News, Podcasts, and Study Results

http://www.eurekalert.org/pub_releases/2016-03/eec...


Multi-gene test identifies early breast cancer patients who can be spared chemo

· Share on FacebookShare on Twitter

Comments

  • Fallleaves
    Fallleaves Member Posts: 806
    edited March 2016

    In addition, the follow-up trial, WSG-ADAPT, has already enrolled more than 4000 patients to look at combining the RS with the assessment of early response to short-term preoperative anti-hormonal therapy as indicated by a decrease in Ki67. "The combination of both tools may help to omit adjuvant chemotherapy in about 50-60% of early breast cancer patients," said Dr Gluz.

    Excellent!

    · Share on FacebookShare on Twitter
  • BarredOwl
    BarredOwl Member Posts: 2,433
    edited March 2016

    Thanks cp418!

    Here is a link to the original abstract re the 21-gene Recurrence Score (RS) assay (OncotypeDX):

    Abstract 8LBA: "Prospective WSG Phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2- high risk node-negative and –positive breast cancer," O. Gluz et al., presented at the 10th European Breast Cancer Conference (EBCC-10) in Amsterdam, The Netherlands, 9-11 March 2016

    http://www.ecco-org.eu/Events/EBCC10/Abstract-sear...

    BarredOwl

    · Share on FacebookShare on Twitter
  • labelle
    labelle Member Posts: 721
    edited March 2016

    Studies like this are very good news and reassuring for those of us with a positive node who skipped chemo based our oncotype scores. Sometimes I've second guessed that part of my treatment plan since a positive node used to mean chemo automatically. Thanks for posting this.

    · Share on FacebookShare on Twitter
  • BarredOwl
    BarredOwl Member Posts: 2,433
    edited March 2016

    From what I can tell, in this study, chemotherapy was only omitted in patients with Recurrence Score RS ≤ 11:

    "Following an early amendment, HR+, pN0–1 patients with RS ≤ 11 were recommended to omit adjuvant chemotherapy (CT). Patients with RS of 12 or above were randomized to 6× TC vs. 4× EC- 4× Docetaxel chemotherapy."

    Patients with Recurrence Scores RS = 12 or above received chemotherapy ("CT"). They were randomized to receive one of two different chemotherapy regimens under comparison:

    (a) anthracycline-containing (four cycles of epirubicin/cyclophosphamide followed by four cycles of docetaxel)

    (b) anthracycline-free (six cycles of docetaxel/cyclophosphamide).

    BarredOwl

    · Share on FacebookShare on Twitter

Categories